Market Lifecycle Stage
The global chronic hepatitis B market is currently in the growth stage, driven by significant advancements in the diagnosis and treatment of the disease. The market is evolving as new therapeutic options, such as gene-editing technologies and immune modulation therapies, move closer to regulatory approval. As clinical trials for these advanced therapies progress, they present an opportunity for market expansion and disruption. These emerging therapies are expected to drive the growth of the market. However, challenges such as high treatment costs and the need for improved accessibility will influence the market dynamics moving forward. The innovation and the successful commercialization of new treatments will shape its trajectory in the coming years.
Impact
Increasing demand for chronic hepatitis B therapies is anticipated to support the growth of the global chronic hepatitis B market during the forecast period 2025-2035.
The global chronic hepatitis B market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.
North America is expected to dominate the global chronic hepatitis B market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global chronic hepatitis B market.
Recent Developments
Regulatory Activities: In April 2025, the U.S. FDA granted fast-track status to PBGENE-HBV, Precision Biosciences’ gene-editing therapy candidate for chronic hepatitis B, which was subsequently tested in patients during a Phase 1 clinical trial.
Funding Activities: In December 2024, AusperBio Therapeutics, Inc. announced the successful completion of a $73 million Series B financing.
Demand – Drivers and Limitations
The following are the drivers for the global chronic hepatitis B market:
Rising Prevalence of Chronic Hepatitis B
Continuous Advancements in Treatment Options
Growing Awareness and Screening Initiatives
Supportive Government Policies and Vaccination Programs
The global chronic hepatitis B market is expected to face some limitations, too, due to the following challenges:
High Treatment Costs
Limited Access to Healthcare in Endemic Regions
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: Product launches and innovations in the global chronic hepatitis B market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Brii Biosciences Limited and Precision Biosciences, have been involved in the development of therapies for chronic hepatitis B.
Competitive Strategy: Enterprises led by market leaders in the global chronic hepatitis B market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
Arrowhead Pharmaceuticals Inc.
Ascletis Pharmaceuticals
Arbutus Biopharma Corporation
AusperBio Therapeutics, Inc.
Gyre Therapeutics
Brii Biosciences Limited
Sino Biopharmaceutical Limited
Gilead Sciences, Inc.
GlaxoSmithKline
Ionis Pharmaceuticals, Inc.
Johnson & Johnson
Precision Bioscience
Vir Biotechnology, Inc.
Virion Therapeutics, LLC
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- Executive Summary
- Scope of Study
- 1. Global Chronic Hepatitis B Market Overview
- 1.1 Industry Outlook
- 1.1.1 Introduction
- 1.1.2 Market Overview and Ecosystem
- 1.1.3 Epidemiological Analysis of Chronic Hepatitis B
- 1.1.3.1 By Region
- 1.1.4 Ongoing Clinical Trials
- 1.1.5 Market Trends
- 1.1.6 Regulatory Landscape / Compliance
- 1.1.6.1 Legal Requirement and Framework in the U.S.
- 1.1.6.2 Legal Requirement and Framework in the E.U.
- 1.1.6.3 Legal Requirement and Framework in Asia-Pacific
- 1.1.6.4 Legal Requirement and Framework in Rest-of-the-World
- 1.2 Market Dynamics
- 1.2.1 Impact Analysis
- 1.2.2 Market Drivers
- 1.2.3 Market Restraints
- 1.2.4 Market Opportunities
- 2. Global Chronic Hepatitis B Market, By Region, $Million, 2023-2035
- 2.1 North America
- 2.1.1 Key Findings
- 2.1.2 Market Dynamics
- 2.1.3 Market Sizing and Forecast
- 2.1.3.1 North America Chronic Hepatitis B Market (by Country)
- 2.1.3.2 U.S.
- 2.1.3.3 Canada
- 2.2 Europe
- 2.2.1 Key Findings
- 2.2.2 Market Dynamics
- 2.2.3 Market Sizing and Forecast
- 2.2.3.1 Europe Chronic Hepatitis B Market (by Country)
- 2.2.3.1.1 U.K.
- 2.2.3.1.2 Germany
- 2.2.3.1.3 France
- 2.2.3.1.4 Italy
- 2.2.3.1.5 Spain
- 2.2.3.1.6 Rest-of-Europe
- 2.3 Asia-Pacific
- 2.3.1 Key Findings
- 2.3.2 Market Dynamics
- 2.3.3 Market Sizing and Forecast
- 2.3.3.1 Asia-Pacific Chronic Hepatitis B Market (by Country)
- 2.3.3.1.1 Japan
- 2.3.3.1.2 China
- 2.3.3.1.3 India
- 2.3.3.1.4 Australia
- 2.3.3.1.5 South Korea
- 2.3.3.1.6 Rest-of-Asia-Pacific
- 2.4 Rest-of-the-World
- 2.4.1 Key Findings
- 2.4.2 Market Dynamics
- 2.4.3 Market Size and Forecast
- 3. Global Chronic Hepatitis B Market - Competitive Benchmarking and Company Profiles
- 3.1 Competitive Benchmarking
- 3.2 Competitive Landscape
- 3.2.1 Key Strategies and Developments by Company
- 3.2.1.1 Funding Activities
- 3.2.1.2 Mergers and Acquisitions
- 3.2.1.3 Regulatory Approvals
- 3.2.1.4 Partnerships, Collaborations and Business Expansions
- 3.2.2 Key Developments Analysis
- 3.3 Company Profiles
- 3.3.1 Gilead Sciences, Inc.
- 3.3.1.1 Company Overview
- 3.3.1.2 Product Portfolio
- 3.3.1.3 Target Customers/End Users
- 3.3.1.4 Analyst View
- 3.3.2 GlaxoSmithKline
- 3.3.2.1 Company Overview
- 3.3.2.2 Product Portfolio
- 3.3.2.3 Target Customers/End Users
- 3.3.2.4 Analyst View
- 3.3.3 Ionis Pharmaceuticals, Inc.
- 3.3.3.1 Company Overview
- 3.3.3.2 Product Portfolio
- 3.3.3.3 Target Customers/End Users
- 3.3.3.4 Analyst View
- 3.3.4 Gyre Therapeutics
- 3.3.4.1 Company Overview
- 3.3.4.2 Product Portfolio
- 3.3.4.3 Target Customers/End Users
- 3.3.4.4 Analyst View
- 3.3.5 Ascletis Pharmaceuticals
- 3.3.5.1 Company Overview
- 3.3.5.2 Product Portfolio
- 3.3.5.3 Target Customers/End Users
- 3.3.5.4 Analyst View
- 3.3.6 Vir Biotechnology, Inc.
- 3.3.6.1 Company Overview
- 3.3.6.2 Product Portfolio
- 3.3.6.3 Target Customers/End Users
- 3.3.6.4 Analyst View
- 3.3.7 Brii Biosciences Limited
- 3.3.7.1 Company Overview
- 3.3.7.2 Product Portfolio
- 3.3.7.3 Target Customers/End Users
- 3.3.7.4 Analyst View
- 3.3.8 Arrowhead Pharmaceuticals Inc.
- 3.3.8.1 Company Overview
- 3.3.8.2 Product Portfolio
- 3.3.8.3 Target Customers/End Users
- 3.3.8.4 Analyst View
- 3.3.9 Johnson & Johnson
- 3.3.9.1 Company Overview
- 3.3.9.2 Product Portfolio
- 3.3.9.3 Target Customers/End Users
- 3.3.9.4 Analyst View
- 3.3.10 Sino Biopharmaceutical Limited
- 3.3.10.1 Company Overview
- 3.3.10.2 Product Portfolio
- 3.3.10.3 Target Customers/End Users
- 3.3.10.4 Analyst View
- 3.3.11 Arbutus Biopharma Corporation
- 3.3.11.1 Company Overview
- 3.3.11.2 Product Portfolio
- 3.3.11.3 Target Customers/End Users
- 3.3.11.4 Analyst View
- 3.3.12 Virion Therapeutics, LLC
- 3.3.12.1 Company Overview
- 3.3.12.2 Product Portfolio
- 3.3.12.3 Target Customers/End Users
- 3.3.12.4 Analyst View
- 3.3.13 AusperBio Therapeutics, Inc.
- 3.3.13.1 Company Overview
- 3.3.13.2 Product Portfolio
- 3.3.13.3 Target Customers/End Users
- 3.3.13.4 Analyst View
- 3.3.14 Precision Bioscience
- 3.3.14.1 Company Overview
- 3.3.14.2 Product Portfolio
- 3.3.14.3 Target Customers/End Users
- 3.3.14.4 Analyst View
- 4. Research Methodology
- List of Figures
- Figure: Global Chronic Hepatitis B Market, Market Overview
- Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, U.S.
- Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, EU5
- Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, Rest-of-the-World
- Figure: Global Chronic Hepatitis B Market Coverage
- Figure: Global Chronic Hepatitis B Market Key Trends, Impact Analysis, 2023-2035
- Figure: Global Chronic Hepatitis B Market, Competitive Landscape, January 2022-April 2025
- List of Tables
- Table: Global Chronic Hepatitis B Market, Regulatory Scenario
- Table: Global Chronic Hepatitis B Market Dynamics, Impact Analysis
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook